Professional Documents
Culture Documents
The States research sector brings expertise in engineering, physics, mathematics, health and medical research critical technologies in device development. Industry and Investment NSW (I&I NSW) is the economic development agency of NSW. I&I NSW can facilitate doing business with NSW organisations by: Helping locate, identify and develop relationships with the right NSW supplier Providing insight on NSW research and development capabilities Facilitating introductions to NSW businesses.
health-related software
Contents
Steering Australias research Roxby Media Australia Suite 804, Level 8, 37 Bligh Street Sydney NSW 2000, Australia Phone: +61 2 8246 7400 www.roxbymedia.com.au Editor: Dominic Cadden Art Director/Cover Design: Anthea Vandertouw Graphic Design/Magazine Layout: Stew OBrien Media & Events Manager: Sandra Johansson Sales Manager: Ben OBrien Group Manager, Specialist Projects: Bruce Jenner CEO: David Collett
4 6 7 8 13 14 18 22 23 24 26 28 30 32 36 38 41 42 44 46 47
Australias next wave of health innovation A proud history of innovation Molecularly targeted therapy
Association of Australian Medical Research Institutes Australias influence on the world of healthcare Peter MacCallum Cancer Centre
Healthcare education
Help Yours
Imagine having Australias leading researchers at your fingertips.
Your Open Innovation partner is literally only a click away Youll have access to the best scientists, researchers and technology developments at one of Australias leading universities. Best of all, were actually seeking Open Innovation Partners to license or co-develop breakthrough innovations. We are NewSouth Innovations Pty Limited, a company owned by the University of New South Wales in Sydney, Australia and were dedicated to helping researchers make a difference. To view our technology portfolio or to engage with us please click www.nsinnovations.com.au
2 INNOVATION IN HEALTHCARE & MEDICAL TECHNOLOGIES
Clever Country
Professor Julie Campbell AO, FAA President, Association of Australian Medical Research Institutes Director, The Wesley Research Institute
This new endeavour signals an important change towards greater integration of health research, education and primary care
This year, nine leading research institutions and hospitals will come together to form Australias first Academic Health Science Centre (AHSC). This new collaborative endeavour signals an important change towards greater integration of health research, education and primary care in Australia. Such centres should accelerate the translation of research innovations into clinical practice. As President of the Association of Australian Medical Research Institutes, the peak body representing Australias independent medical research institutes, I am excited to see our member institutes playing a central role in the introduction of AHSCs. In addition, stronger links between research and primary care will embed innovation into our nations health system to allow it to responsive to the needs of Australias ageing population.
1. The Virtuous Circle: Working Together for Health and Medical Research - Health and Medical Strategic Review. Commonwealth of Australia, Canberra. 1999. 2. Sustaining the virtuous cycle for a healthy, competitive Australia. Investment Review of Health and Medical Research. Final report. Commonwealth of Australia, Canberra. 2004.
Contact: National Health and Medical Research Council (NHMRC) Tel: +61 2 6217 9000 Fax: 61 2 6217 9100 E-mail: nhmrc@nhmrc.gov.au Website: www.nhmrc.gov.au
reputation in health and medical research through international participation. More significantly however, the NHMRC is, through its funding, contributing to a greater critical mass to major health problems that need research. This critical mass is essential to ensuring that health and medical research directly contributes to overcoming the burden of disease that is still affecting so many people around the world. The NHMRC is also working to ensure that ethical guidelines, and health advice are developed internationally. This enhances the capacity of research, when conducted to the highest standards, to be an effective use of resources and also ensures that research results are translated into meaningful change.
INTERNATIONAL ENGAGEMENTS
NHMRC is actively working to strengthen Australias international
research funding from other international funding bodies; create opportunities for researchers to be involved in major international collaborative activities and influence their development; and provide research support through access to techniques and technologies not yet available in Australia.
These partnerships include: European Union Collaborative Research Grants Scheme Projects involving Australian researchers based in Australia that are chosen by the European Commission (EC) for funding through the Seventh Framework Programme (FP7) may be eligible for NHMRC support. The total NHMRC funds available under this scheme each year is A$4 million. European Molecular Biology Laboratories Network NHMRC funds a program leader to work in a European laboratory and forge links between that laboratory and Australian researchers. The positions are available for five years in Europe. Human Frontier Science Program (HSFP) HFSP supports novel, innovative and interdisciplinary basic research focused on the complex mechanisms of living organisms. Research emphasises novel collaborations that bring biologists together with scientists from fields such as physics, mathematics, chemistry, computer science and engineering to focus on problems at the frontier of the life sciences. More than 30 countries worldwide are involved, including the NHMRC that has committed US$2.54 million to this program.
International Cancer Genome Consortium This program is the largest international effort to obtain a comprehensive understanding of genomic, transcriptomic and epigenomic changes in 50 different tumour types and/or subtypes that are of clinical and societal importance across the globe. The Australian Government will provide A$27.5 million over five years through the NHMRC to fund research into pancreatic and ovarian cancers. Global Alliance for Chronic Disease The Alliance is formed by six of the worlds peak health and medical research funding agencies, which represent 80 per cent of the worlds health and medical research funding. Through NHMRC, Australia is working with the other GACD members to coordinate research activities addressing the prevention and treatment of chronic noncommunicable disease, such as hypertension, on a global scale. This first call from the GACD, in April 2011, will target the almost one billion people worldwide who have high blood pressure. It will seek to identify why this pandemic is occurring despite the progress that is being made towards the prevention and treatment of hypertension. International Stem Cell Forum This is a collaboration of 14 national and private research funding organisations that are working together to facilitate international collaboration in stem cell research. UK Human Genetics Commission An international collaboration on genetics issues leading to a
harmonised approach to genetics across jurisdictions. Heads of International Research Organisations Most major national and private funding bodies are represented, including the Bill and Melinda Gates Foundation. Meetings are held every six months to discuss important issues facing all funding bodies.
1. L Butler & K Henadeera, National Health and Medical Research Council, Measuring Up 2009: NHMRC - Supported Research. The Impact of journal publication output 2002-2009, February 2009
Biotechnology
also provides advice and guidance to investments overseas, analyses joint venture opportunities, organises market research and intelligence and competitor analysis and helps the development of strategies to enter a specific market. Austrades Biotech team not only assists Australian business with trade and investment overseas, but also facilitates the process of finding Australian suppliers for foreign companies, finding
Health Innovation
Contact: Dr Peter Cook, ASSOCIATION OF AUSTRALIAN MEDICAL RESEARCH INSTITUTES Tel: +61 7 37211709 E-mail: pcook@wesleyresearch.com.au Website: www.aamri.org
exciting opportunity to overcome these limitations, which put many lives at risk. Centre for Eye Research Australia researcher, Professor Donald Martin, received funding to trial a non-invasive system for delivering drugs to the interior of the eye. If successful, this technology may mean the end of frequent, painful eye injections for patients suffering from age-related macular degeneration. The drug delivery is via a gel placed over the eye. A device attached to the gel produces ultrasonic pulses that propel this drug from the gel into the eye. CERA Research Fellow Dr Paul Connell said, The device uses an innovative combination of nanotechnology and ultrasound to deliver a non-invasive and painless dose of medication that can specifically target the retina at the back of the eye. These projects demonstrate the diversity of leading edge research being undertaken within Australias MRIs and the latest innovations that may be helping patients in the future.
a team that will investigate the development of a system to generate red blood cells from human embryonic stem cells. The successful development of this stem cell technology may overcome problems associated with the supply and delivery of donor blood for lifesaving transfusions. Red blood cell transfusions can be life-saving, however demand for banked blood continues to outpace the supply, Dr Carotta said. Access to blood transfusions is limited by a lack of donors, lack of blood of the correct type, and short shelf-life of blood and blood products. Stem cells provide an
Dr Fiona Stanley discovered a lowcost prevention against this serious birth defect that can affect the legs and feet, bowel, bladder and brain: folate. Its easy to find folate is the naturally occurring form of folic acid or vitamin B9 found in many vegetable, fortified grain products and seeds, but folate tablets are also readily available. Increased folate intake one month before conception and daily during the first three months of pregnancy can prevent up to 70 per cent of spina bifida cases, and this knowledge has seen spina bifida cases in newborns plummet across the world.
Counting areas of influenza virus growth in cell culture, a technique for assessing efficacy of anti-influenza drug Relenza.
Credit: CSIRO Molecular & Health Technologies
COCHLEAR IMPLANT
The cochlear implant has helped thousands of people to hear clearly again. When used with a microphone and speech processor, the implant electrically stimulates the auditory nerve and results in the person being able to hear sound. After years of research and improvements, enough funds were raised to make and test a prototype of Professor Graeme Clarks
The interaction of the anti-influenza drug Relenza, buried in the active site pocket of influenza virus neuraminidase protein. Credit: CSIRO Molecular & Health Technologies
has four valves and if even one fails, it has to be replaced. Dr Chang was concerned about the lack of organ donors and consequently began work on an artificial heart before his death.
SPRAY-ON SKIN
In 1992, plastic surgeon Dr Fiona Wood saw a school teacher at Perth Hospital with petrol burns to 90 per cent of her body. At the time, skin culturing technology took 21 days to develop enough skin to cover major burns. Dr Wood developed techniques that cut this to just five days, which sped up healing and significantly reduced scarring. The Bali bombings of 2002
An Audio Processor with earmould for Electric Acoustic Stimulation (the use of a hearing aid and a cochlear implant together in the same ear) worn by user.
invention. The commercialisation of the product began with the introduction of Nucleus(r) 22 in 1983, after a partnership between University of Melbourne, Nucleus and the Federal Government. This collaboration led to the creation of Cochlear Pty Ltd, an Australian company specialising in the cochlear implant.
Ring forms of the Plasmodium falciparum (malaria) parasite, inside red blood cells.
Credit: MichaelZahniser
occurred before this process could be clinically evaluated, but several of the worst victims were flown to Perth Hospital for treatment, where Dr Woods pioneering technique substantially reduced the death toll among these horrific burns cases.
by the human papillomavirus (HPV), and after parallel research with their American counterparts, Professor Ian Frazer and others at the University of Queensland developed a vaccine against the virus. The HPV vaccine became available in Australia in 2007.
INSULIN GEL
Australia is giving diabetics the world over a chance for life without the needle. In 2010 Melbourne company Phosphagenics will conduct second phase of human trials for a form of insulin that can be absorbed through the skin. That means that for both type 1 and type 2 diabetes sufferers a slow-release insulin patch could cut the need for or even replace needles.
PILLCAM
Dr Andre Chong and his team of researchers at St Vincents Hospital in Melbourne made a 27mm-long capsule housing a tiny camera. A quick swallow can now often replace the need for uncomfortable colonoscopies and endoscopies, and it does a better job than either of investigating the notoriously difficult-to-visualise small intestine. Every half-second the capsule transmits digital images to a recording device. Since
widespread use began in 2003, this has been a blessing for people with obscure gastro-intestinal bleeding or suspected small bowel Crohns disease.
RECALDENT
More than 15 years of research at Melbourne University led to the development of Recaldent. Professor Eric Reynolds, Head of the School of Dental Science, wanted to find a way that calcium and phosphate from cows milk could repair damaged tooth enamel. His team of researchers came up with a compound derived from milk proteins that could bind to teeth and provide a reservoir of calcium and phosphate on the tooths surface that could be absorbed by the tooth enamel. Today, Recaldent is incorporated into products such as chewing gum, toothpaste and mouthwash.
HPV VACCINE
Cervical cancer is the second most common cause of cancer death in women worldwide, but Australia helped cut down this scourge of womens health. About 70 per cent of cervical cancer cases are caused
SOLARSCAN
Solarscan completely swung the battle against skin cancer. Developed in 1998 through Polartechnics Ltd, the Sydney Melanoma Unit and the CSIRO, the Solarscan quickly detect melanomas. A camera takes a
10
second sprints on a stationary bike followed by 12 seconds of cycling lightly produced much better results than the typical, steady-pace, low intensity 40 minute workout, and researchers suggested this format would also work for other cardio activities. Chemical compounds called catecholamines are produced from interval sprinting, and its thought that these drive the greater weight loss.
CADUCEUS
Dr Kim Branson was a PhD student at CSIRO Health Sciences
& Nutrition and the Walter & Eliza Hall Institute (University of Melbourne) when he designed and built the Caduceus supercomputer in 2000. Sixty-four computers linked together in a Beowulf cluster (high-performance parallel computing clusters of inexpensive personal computer hardware) form Caduceus, which designs and evaluate new drugs by screening millions of chemical compounds from a variety of sources to then identify possible drugs. Not only is the process incredibly fast, it also replaces labour-intensive lab testing.
picture of a suspicious spot and stores the image on a computer, where it is magnified and enhanced to remove hairs and oil. Special software analyses the image against a databank to determine whether the spot it is likely to be a melanoma.
The Beowulf cluster caduceus used for the identification of novel drugs in silico.
Credit: Mark Fergus, CSIRO Molecular & Health Technologies
11
12
Australian success
Contact: Peter Macs Communications Tel: +61 3 9656 5883 E-mail: emma.liepa@petermac.org Website: www.petermac.org
Scans of a patient with melanoma treated with a BRAF inhibitor. Multiple deposits in the abdomen involving the small bowel are typically very difficult to detect on CT but are clearly visualised because of their high glucose use on FDG PET/CT.
unchanged during clinical trials in cancer. The fact we can do a gene test, identify mutations and develop a drug thats specifically designed to inhibit that mutation in the cancer cell and achieve this strike rate, even in early stages of trial, is an exciting development. These results indicate a highly promising way to combat melanoma in its more advanced stages, providing patients that have progressive disease with a new treatment option. Supporting this exciting trial is the Melbourne Melanoma Project (MMP), established with Victorian Government funding as a collaboration between clinicians, pathologists, molecular biologists, the Victorian Cancer Biobank, Biogrid Australia and major Melbourne melanoma services at Peter Mac, the Alfred and Austin
hospitals. The MMP aims to further unlock the molecular secrets of melanoma and develop more, new therapeutic strategies by identifying further specific molecular targets, and links the collection of clinical and outcome data from melanoma patients with routine molecular evaluation of patients melanomas. The project is emblematic of Peter Macs belief that innovative collaborations bringing together the brightest minds in cancer research and the clinic will lead to faster discoveries and advances in clinical care. There are various genome projects underway conducting DNA sequencing in cancer. Within five years we will have identified all the major mutations in all the common cancers, says Associate Professor McArthur. It really is a new era for cancer research.
13
Contact: Catherine West, Snr Executive Officer, THE AUSTRALIAN SOCIETY FOR MEDICAL RESEARCH Tel: + 61 2 9526 5450 E-mail: asmr@alwaysonline.net.au Website: www.asmr.org.au
2008 ASMR Medallist Sir Gustav Nossal gives his presentation at the Perth Gala Dinner during ASMR Medical Research Week
Healthcare
the ups and downs often only avoided by concentrated lobbying efforts from the medical research community. These downs have, and will continue to have, devastating effects on the workforce and health outcomes if they continue to occur.
Established in 1961, ASMR is a non-profit, independent society with the goal of fostering excellence in health and medical research. Our long tradition of public, political and scientific advocacy continues as we inform debates on scientific issues, promote scientific excellence and cross-collaborations, increase community understanding of the benefits and achievements of HMR, and campaign for stable and appropriate funding to maintain an internationally competitive health and medical research program.
14
Healthcare
Winners of prizes for excellent oral presentations at an ASMR Scientific Symposium during ASMR Medical Research Week.
now face the difficult task of implementing an effective, selfimproving healthcare system robust enough to deal with the unprecedented challenges of an ageing population, the escalating burden of chronic, lifestyle-related diseases and a disproportionate disease incidence among our indigenous population. Predicted healthcare costs associated with these issues are frightening the Governments own Intergenerational Report 2010 (a projected assessment of the nations demographic, economic and social makeup forward to 2050), makes for very sobering reading. Here is just one example, and a very appropriate one in the context of Australias increasingly ageing population: dementia is a disease predominantly affecting older people and it is a significant health problem in Australia, with currently just under a quarter of a million sufferers and projected increases to over 1.1 million by 2050. The cost in terms of human suffering is incalculable, and the cost in terms of health expenditure will, by the 2060s, outstrip that of any other health condition. Addressing these future healthcare challenges will not be easy it will
require a broad and encompassing long-term vision and a focus on utilising the nations resources, particularly our human capital, more effectively while exploring novel approaches to alleviate the burdens on the current system. The recent focus on health reform also presents an opportunity to emphasise to both state and federal government that the efficient and effective delivery of healthcare is critically underpinned by a vibrant and productive HMR sector. Indeed, the broad spectrum of basic and applied HMR informs and facilitates the process of healthcare delivery at every stage, from the identification of preventative health measures through to the development and delivery of more effective treatments for patients.
knowledge through research. This doesnt just make sense in a social context by alleviating the burden of disease and keeping people out of hospitals in the first place, but it also leads to significant economic benefits by keeping them in the workforce longer, leading healthier more productive lives. The Australian HMR sector is in a strong position to respond readily to these new challenges. We boast a highly skilled and productive workforce, with a proven track record of world-class bench to bedside research. Such a vital skill base requires solid and appropriate
Prof Prue Hart presents to medical researchers at an ASMR Professional Development Day.
15
funding to continue its exceptional level of productivity funding that also recognises and encourages innovative, blue-sky research. This will provide the underpinning not only for new discovery, but also for the reformed health system to become a truly self-evaluating, self-improving organisation. There is also an increasing recognition of the value of a HMR sector that links universities, research institutes, public health agencies, primary care and teaching hospitals enabling the reverse concept of bedside to bench clinical issues informing and driving basic research to flourish.
4000 knowledge-based jobs resulting from the development of health and medical research discoveries. The report indicated that for every A$1 invested in health and medical research, there is an average of $2.2-$6 return to Australias economy. Other impressive economic findings of the study include expenditure on Australian health R&D between 1992/3 and 2004/5, estimated to return a net benefit of around A$29.5 billion, and that compared to return on investment, health R&D outperforms the market and is less only to that of mining and the retail/wholesale trade sectors. Moreover case studies suggest that further investment in four areas critical for the future health of Australians diabetes, dementia, cancer, and indigenous health will yield considerable health and economic and benefits. It is timely that Australia also looks beyond its shores and puts under the microscope countries that have a major long-term economic commitment to innovation, science, research and industry. The most ambitious program in the world is the European Framework 7 Programme. Thirty years in the making, the Framework 7 Programme has the commitment
of 27 European countries to invest three per cent gross domestic product (GDP) in R&D. Some already exceed this level. The result is a dynamic research community which is building in momentum. Australia needs to be outward looking and explore funding mechanisms that suit our culture, add value to existing domestic systems and embrace the Asia Pacific region. The ASMR recently bought together an eminent panel to discuss the possibilities, opportunities and challenges presented by an AsiaPacific Health and Medical Research Funding Union, which agreed that the genesis and implementation of such an initiative could only enhance the health, economy and stability of the region. In this exhilarating climate of change and reform in Australias healthcare system, the implementation of the health reform agenda is an opportunity for the Australian government to make a real difference to the delivery of effective healthcare in this country, in all its aspects an opportunity that we, as a nation, literally cant afford to squander. But it is also a timely imperative for Australias HMR community to step up and claim a place at the discussion table, actively engaging government in a productive dialogue aimed at facilitating the integration of research into that new and improved healthcare system. Government investment in health and medical research is an essential element of the healthcare of a nation. The level of that investment must realistically reflect the health needs of that nation. It is time to redress the traditional disconnect between HMR, often viewed as an admirable, but somewhat intellectual pursuit, and the delivery of better health outcomes for all Australians.
Healthcare
16
17
Contact: Dianne Lavender, Public Relations Manager, GARVAN RESEARCH FOUNDATION 384 Victoria Street, Darlinghurst NSW 2010 Tel: +61 2 9295 8116 E-mail: d.lavender@garvan.org.au Website: www.garvan.org.au
Neurodegenerative Disease
... showing how nerve cells in the brain produce an anti-inflammatory molecule that allows the brain to repair itself may possibly change the way we think about treating neurodegenerative diseases
Dr Doyle is also seeking to understand the molecular process underlying adult stem cell differentiation that is, the trigger driving a particular differentiation pathway. Understanding this process and the optimal environment for stem cell differentiation (or stem cell niche), it may then be possible to turn these triggers on within the brain without Parkinsons patients have lost at least 70 per cent of their dopamineproducing cells by the time symptoms appear. Secondly, it may be possible to identify drug targets to inhibit the processes leading to cell death. Dr Cooper is also looking for new genes (and their proteins) with links to Parkinsons disease in order to
18
Neurodegenerative Disease
understand why, when a particular gene is dysfunctional, the cell becomes more susceptible to failure leading to disease onset. Dr Coopers research is also focused on the interaction between the genes known to play a key role in Parkinsons, specifically PARK9 and alpha -synuclein. Scientists have known for some time that overexpression of PARK9 is toxic and has been found in abundance in the brains of deceased Parkinsons sufferers. In one of his recent findings using yeast, Dr Cooper and collaborators discovered a critical connection between these two genes. Yeasts are single-cell organisms that are widely used in biological research because their structure resembles that of cells found in animals and humans. PARK9 is found in yeast and alphasynuclein can be introduced to yeast, making it possible to analyse their function. He found that high levels of PARK9 in a cell significantly diminished the toxic effects of alpha-synuclein. PARK9 also appears to be a manganese pump capable in theory of removing excess levels of this metal from cells an important finding because manganese poisoning can also cause Parkinsons-like symptoms. This work showed for the first time the connection between three pieces of the Parkinsons disease jigsaw PARK9, alpha-synuclein and manganese. Drs James Daniel and Bryce Vissel in the Neuroscience program have been looking at Parkinsons disease from another perspective. Findings from their recent research have significantly advanced our understanding of dopamine release from nerve cells and may speed the development of more effective drugs for treating Parkinsons disease. The primary symptoms of Parkinsons (rigidity, tremor and impairment
of physical movement) are caused by the loss of dopamine-producing nerve cells in the brain. Medicines used for treating Parkinsons either provide extra dopamine or attach to the remaining nerve cells that release dopamine and regulate its release. In the latter case, no-one
process that takes place at the dopamine nerve cell synapse. Their findings may help work out how drugs currently being used to treat Parkinsons disease are regulating dopamine release. It will also open up new avenues for pharmaceutical development.
Neurons showing the localisation of scapinin (in blue), an important protein that regulates the outgrowth of neurites and helps establish connections between neurons so that they can exchange information.
understands the mechanisms involved, or how to control them. When an electrical impulse reaches the end of a dopamine nerve cell, called a synapse, it sometimes stimulates the release of dopamine yet more often it doesnt. Only about one in five impulses cause dopamine release, and the release rhythm is irregular. Drs Daniel and Vissel have developed a mathematical model and microscopy method that reveal the mechanisms behind synaptic dopamine release and the factors that govern the probability of release. Their work involved developing sophisticated statistical analysis protocols and mathematical models of synapses to help de-mystify the part of the
Further work in Dr Vissels lab has shown that nerve cells in the brain produce an anti-inflammatory molecule that allows the brain to repair itself, possibly changing the way we think about treating neurodegenerative diseases. Drs Vissel and Andrea Abdipranoto, seeking to understand what drives and blocks this regeneration, found high levels of a molecule known as Activin A released from nerve cells whenever regeneration occurred in the brains of mice. It seemed that nerve cells may directly drive regeneration by released Activin A. Further experiments showed that the main role of Activin A was to block inflammation in the brain after neurodegeneration or injury. While inflammation is the bodys way of protecting itself against
19
Neurodegenerative Disease
Researchers believe that chronic inflammation is probably pro iding a harmful feedback loop, preventing regeneration and contributing to progressive decline
harmful irritants or damaged cells, these findings highlight that if left uncontrolled, inflammation can prevent regeneration and healing. It is likely that inflammation aggravates existing damage in the central nervous system of people with Parkinsons, Alzheimers and motor neurone disease. The researchers believe that chronic inflammation is probably providing a harmful feedback loop, preventing regeneration and contributing to progressive decline. If further research confirms that inflammation is blocking regeneration in these diseases, Activin A and derivatives need to be investigated as potential therapeutics. Work by Garvans Neurosignalling group led by Dr Adam Cole investigates the molecular mechanisms involved in synaptic plasticity, which deteriorates dramatically in neurodegenerative disease. By understanding how synaptic plasticity works in a healthy brain it may be possible to develop strategies to enhance brain function and specifically the ability to learn new things, retain and recall information. For sufferers of neurodegenerative diseases this understanding may help delay or prevent the onset of disease and possibly help compensate for the loss of brain function.
The Neurosignalling group is focused on 3 enzymes (Cdk5, GSK3 and PCTK2) known as kinases found in the brain, which are important for neurotransmission and regulation of synaptic plasticity. The group is working to better understand why changes to their activity contribute to brain dysfunction during ageing and in dementias such as Alzheimers disease. In previous research, Dr Cole discovered a brain protein called CRMP2 that is excessively modified in the brains of Alzheimers disease patients. He found that this occurred early in the disease process and was specific for Alzheimers disease, giving it great promise as a diagnostic biomarker for early and specific detection of Alzheimers disease.
Dopaminergic neuron.
In recent work, he discovered a similar brain protein called -adducin that is also found in red blood cells. Since blood is more accessible for diagnostic purposes, this poses the exciting possibility that -adducin might serve as an early stage, blood-based biomarker for Alzheimers disease. If so, this would greatly assist in earlier diagnosis of Alzheimers disease, when patients are more receptive to drug therapy.
20
The States research sector brings expertise in engineering, physics, mathematics, health and medical research critical technologies in device development. Industry and Investment NSW (I&I NSW) is the economic development agency of NSW. I&I NSW can facilitate doing business with NSW organisations by: Helping locate, identify and develop relationships with the right NSW supplier Providing insight on NSW research and development capabilities Facilitating introductions to NSW businesses.
health-related software
21
The Stem Cells Australia application showed innovative research ideas and strong leadership skills, both of which are necessary to give us
...we need solutions to save lives, impro e quality of life, take pressure off hospitals and, in turn, ease the burden on our economy
Announcing the funding under the Australian Research Council (ARC) Special Research Initiative in Stem Cell Science, Australian Innovation Minister, Senator Kim Carr, and CEO of the Australian Research Council, Professor Margaret Sheil, said the investment could deliver significant breakthroughs in the area of biotechnology and save the lives of many people around the world. a greater understanding of stem cells and hopefully bring about some of the worlds best medical breakthroughs. Heart disease, stroke and multiple sclerosis are common medical problems and we need solutions to save lives, improve quality of life, take pressure off our hospitals and, in turn, ease the burden on our economy, Senator Carr said.
22
The National Imaging Facility (NIF) was established in 2007, as part of the National Collaborative Research Infrastructure Strategy (NCRIS). NCRIS marks a new paradigm for the funding of major infrastructure in Australia, whereby the needs of the community were identified through a nationwide consultation process and access to facilities is based on merit, and must be opened to the wider scientific community. Imaging was identified as a component of the Characterisation Capability, along with the Australian Microscopy and Microanalysis Research Facility, the Australian Synchrotron and the National Deuteration Facility. The Characterisation Council provides support and advice to all four subcapabilities, advising government on further requirements. It also provides a forum, whereby the four sub-capabilities share an ethos for complementary use of technologies, as well as to identify synergies to give a capability that is greater than the sum of its parts. The NIF has recently received a A$40.2m injection from the Education Investment Fund, as part of a $106m expansion program The NIF is strongly aligned, both in its strategic approach and specific objectives, with the recommendations for development of national research capabilities outlined in the 2006 and 2008 Strategic Roadmaps for Australian Research Infrastructure. Consequently, it is supported by the results of extensive consultation with the research community, funding providers, industry and government agencies at state, territory and federal level. The NIF
provides state-of-the-art imaging of animals, plants and materials for the Australian research community, providing a range of leading edge imaging instrumentation. An important component of the NCRIS vision is the provision of resources to the research community, with expert advice and assistance in the optimal use of imaging to the research community. LARIF, the Large Animal Research and Imaging Facility, provides a complete research environment, including operating theatres, animal husbandry and imaging, so that longitudinal experiments can be established and researchers have the confidence that the animals will be cared for, and the needs of the experiments delivered with professionalism. A major focus of the NIF is the development and validation of novel PET and MR biomarkers (drugs and imaging probes) and non-invasive imaging technologies that are used to improve our understanding of disease. It includes access to research cyclotrons, radiopharmaceutical development and molecular imaging, offering a one-stop shop, critical for short-lived isotopes such as C-11, but also the ability to ship tracers based on longer-lived isotopes to other facilities. A further focus is the complementary use of different imaging modalities, other live animal imaging equipment including bioluminescence, microCT, ultrasound and intravital microscopy. NIF has identified simultaneous imaging using different technologies as a key target, and will install the first preclinical MR-PET in Australia, and plans to be able install a human
MR-PET within the next few years. NIF also offers the internationally unique opportunity for extensive complementary pre-clinical and clinical imaging co-located with the Imaging and Therapy Beamline of the Australian Synchrotron. Many of the future developments in NIF will be driven by the need for translation from the preclinical animal research to human clinical research and ultimately, clinical medicine. The next phase will see 7T human MRI, and co-location of MRI with MEG. Biomarkers will be initially evaluated in small animals, and then proven in large animals at LARIF, resulting in a much smaller step in translation to human use. This type of research is greatly enhanced through the commitment of all nodes to collaboration and sharing of expertise. In addition to the instrumentation funded by the initiative, the NIF provides access to a federated bioinformatics capability. A key aim of NIF is to develop databases of normative data, to remove the need for duplication of effort and reduce the number of experiments required for research, with the resulting reduction in instrument time and number of animals used. NIF now extends to 12 institutions, including all Australian universities, with a significant research and education presence in imaging, together with several Medical Research Institutes, ANSTO and SA Pathology. As such, it serves as a springboard for national and international collaborations. www.anif.org.au
23
Leadership in Research
CQUNIVERSITY
Some of its leading scientists are contributing to the worldwide fight against respiratory infections, particularly middle ear infection, which has had terrible consequences for Aboriginal communities as well as the wider population. Up to 80 per cent of Australian children have at least one episode of middle ear infection in their first three years and about one third of
Researchers at the Centre for Mucosal Immunology, CQUniversity - Professor Jennelle Kyd, Dr Ajay Krishnamurthy, Jenifer Alsemgeest, Maree Stocks, Dr John McGrath and Melissa Harling.
24
Leadership in Research
Some of these findings have been translated into human trials examining the outcomes of cardiac rehabilitation programs and workplace activity levels on improving markers of chronic cardiovascular disease. For the past few years, Dr Duncan has been researching the physical activity levels of various groups of people. In 2009, he developed an innovative way of surveying these groups. Rather than relying on people completing written surveys, Dr Duncan is using GPS monitors that show exactly where people have travelled over a given period. Matched with GIS (Geographic Information Systems) maps, he can now gauge whether people have encountered obstacles or disincentives to activity. With surveys people are not always as accurate as they should be and that limits our ability to see how environments influence activity. Dr Duncan a 2010 Queensland Young Tall Poppy Science Award winner now hopes to develop the concept further with a smaller, integrated monitor that could not only measure the paths people take, but also the intensity of the activity. His research centres on the effects of too little physical activity and too much sitting; the influence that community designs and workplace environments have on these behaviours; and how best to measure our behaviour in these environments. Dr Duncan and his colleagues have secured a $896,000 National Health and Medical Research Council (NHMRC) grant for Project WALK 2.0, which investigates the internal and external validity of the latest web applications in promoting physical activity.
CQUNIVERSITY
Dr Kerry Reid-Searl has become known as the masked educator, using roleplay to enhance the learning experience of her students.
CQUniversitys leadership in these areas also extends to its world-class education of medical health sciences. Senior Lecturer Dr Kerry Reid-Searl has become known internationally as the masked educator. The nurse educator uses roleplay to enhance the learning experience of her students and recently she introduced a wig, glasses and a fat suit so students could have a character to interact with. This is how the eccentric character patient known as Iva Sore was born. Iva soon made her way out of the lecture room and made several surprise appearances at medical conferences. It worked well, but there was still a power imbalance because students could still detect the lecturer under the costume, Dr Reid-Searl says. We tried solid masks, but it was not until we found an American company that could make us realistic flexible silicone masks that the idea really took off. Dr Reid-Searl says students have really engaged well with her new characters, epitomised by retired butcher Cyril Smith and former nurse matron Murial Mona Moore. Dr Reid-Searl says the American company has now been approached to make a whole range of authenticlooking wounds and body parts, including breasts, abdomens, genitalia and even colostomies. These resources will be a part of what Dr Reid-Searl is creating as MASK-ED (KRS simulation), which has been recently trademarked. MASK-ED simply means masking of the educator and masking of the educational process, while KRS stands for knowledgeable, realistic and spontaneous simulation. CQUniversity is also in the final stages of establishing an agreement with the company so that silicone props made for MASK-ED will be exclusive. The University will then market MASKEDTM (KRS simulation) props and educational resources. Dr Reid-Searl believes that while the props hide the face of the educator, the skill is in knowing how to use this technique. Hence it is fundamental that the educator is prepared with the educational resources that Dr Reid-Searl has created.
25
Contact: Peter Macs Communications Tel: +61 3 9656 5883 E-mail: emma.liepa@petermac.org Website: www.petermac.org
Cohorts to cures
Peter MacCallum Cancer Centre in Melbourne, Australia is a leader in the development of genomic technologies and their application to human cancers.
Working with colleagues from across Australia and around the world, Peter Mac has developed some of the most valuable patient cancer cohorts involving thousands of individuals that serve as foundation resources for understanding the biology of human cancers and the determinants of patient outcomes. Peter Mac leads national collaborative studies such as the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), the Australian Ovarian Cancer Study and the International Sarcoma Kindred Study. Peter Mac has also become a centre of excellence for genomic technologies, pioneering the use of microarrays and more recently the application of secondgeneration DNA sequencing to the cancer cohorts. Laboratory-based research findings are translated rapidly to clinical practice through Peter Macs Familial Cancer Centre and Molecular Pathology Unit.
risk of developing sarcoma. Early detection by identifying those at risk may lead to better prognosis. The ISKS project will enable continual provision of important practical information for clinicians and patients.
Genomic technologies
Colin House and Dr Andreas Moeller lead a team in Peter Macs Cancer Genetics and Genomics laboratory studying breast cancer progression and its spread to distant organs.
KCONFAB
kConFab is a national multidisciplinary consortium committed to understanding the causes and consequences of familial predisposition to breast cancer and other malignancies. kConFab has so far enrolled over 1300 multicase kindred groups and through its support of research projects has contributed to over 100 papers, including the identification of new breast cancer susceptibility genes and defining the impact of BRCA mutations on the risk of prostate and other cancers.
detailed clinical information and bio-specimens collected, creating one of the largest ovarian cancer cohort studies in the world. AOCS researchers have made significant contributions to understanding the environmental and genetic risk and molecular changes in invasive tumours. Peter Mac established an innovative program and clinical service in human cancer genetics.
26
Peter MacCallum Cancer Centre is Australias only public hospital solely dedicated to cancer and one of an elite group of hospitals worldwide to have its own integrated cancer research program and laboratories.
In the words of Sir Peter MacCallum, Nothing but the best is good enough for the treatment of cancer. This sense of purpose and commitment to making life better for people with cancer continues at Peter Mac. Through a continued commitment to excellence, innovation and compassion, Peter Macs mission is to minimise the impact of cancer on its patients and the community. With over 2000 staff at six sites across Victoria, our clinical services include haematology, medical, surgical and radiation oncology, radiation therapy, same-day chemotherapy, clinical trials, familial cancer, allied health, and a comprehensive range of general and specialist diagnostic, interventional and therapeutic cancer imaging services. Our multi-disciplinary teams, which are organised into 11 tumour streams, specialise in a tumour type and develop comprehensive and coordinated treatment plans, ensuring our patients get treatment and a team tailored to their individual needs. We strongly believe that treatment informed by research, and research informed by treatment, is the key to advancing cancer prevention, diagnosis and treatment. With researchers and clinicians working side-by-side, Peter Mac has made significant contributions to basic research, translational research and clinical trials. Peter Mac is the largest cancer research site in Australia. Our research program encompasses 27 laboratories and over 520 scientists, clinician researchers, research nurses and other health professionals involved in various aspects of cancer research. It attracts students and researchers from around the world. We are heavily involved in planning for our new home as part of the Victorian Comprehensive Cancer Centre Project. Due for completion in 2015, Peter Mac will share this $1 billion facility, to be purpose-built for cancer, with the Parkville branch of the Ludwig Institute for Cancer Research, and parts of The Royal Melbourne Hospital and The University of Melbourne. Peter MacCallum Cancer Centre the best in cancer care, accelerating discovery, translating to cures. To find out more about Peter Mac, visit www.petermac.org or call +61 3 9656 5883. Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne Victoria Australia.
Pictured: Registered Nurse Laura Pyszkowski and Research Nurse Carrie Donohoe with a patient in the Chemotherapy Day Unit. Peter Mac runs a large clinical research program including trials of cancer therapeutics extending from first in man phase I trials to definitive phase III trials. Joint appointments between the divisions of Cancer Medicine and Cancer Research help facilitate early drug development research, while close cooperation with the Translational Research Laboratory permits bench to bedside research, and opportunities to return to the lab to explore observations made in the clinic. INNOVATION IN HEALTHCARE & MEDICAL TECHNOLOGIES 27
e-health in Australia
Illustration: NEHTA
The event foretelling the Australian Governments commitment to modernizing its current health information landscape was the establishment of the National
through to healthcare manager has proven to be less straightforward. Despite the existence of economic stimulation and political impetus for innovation and the subsequent
28
e-health in Australia
justification of e-health spending to political and financial decision-makers over more tangible resources with more acute outcomes; lack of continuity across political leaders and key players at all levels of politics; difficulty in leveraging disparate e-Health currently in place around Australia; shortage of IT skills and specialisation; immaturity of health IT infrastructure and systems, due primarily to lack of prior investment; and difficulties providing infrastructure and broadband access to Australias extensive geography.
million rural Australians spread over a 7.5 million square kilometres, and it is expected to take a $35 billion national broadband network to provide such service to these areas. Such innovations taking place within the healthcare system are not isolated to a rural context, they are occurring across the entire landscape of health reform, resulting in the formation of The Australian E-Health Research Centre (AESHRC), a joint venture between the state government of Queensland and Australias national science agency, CSIRO (Commonwealth Scientific and Industrial Research Organisation). Since its conception in 2003, the AEHRC has developed multiple technologies and solutions as part of the e-health revolution across a wide range of areas, including tools for medical training and skills development, clinical terminology mapping, surveillance database composition, medical imaging technologies relating to Alzheimers and prostate radiotherapy, clinical support and prediction tools, and mobile computing platforms. In rural areas, the Virtual Critical Care Unit (ViCCU) is showing great potential in solving the dilemmas of healthcare inaccessibility by allowing a real-time telepresence
link enabling a specialist team in one hospital to supervise a team treating a critically ill patient in another. RIDES, the Remote Immersive Diagnostic Examination System, is another technology to come from AEHRC that allows specialist surgeons to examine patients in a remote location comprehensively and realistically. ECHONET, (EchoCardiographic Healthcare Online Networking Expertise in Tasmania), enables cardiologists to attend to ICU patients in rural Tasmania. It is situations such as these currently unfolding within the Australian healthcare sector that provide great potential for innovation, technology, and advancement in our capabilities and potential to deliver healthcare. We must keep a watchful eye fixed here and on similar situations globally if we are to successfully identify, nurture and develop further solutions to an increasingly demanding healthcare sector, and ultimately allow us to deliver more efficient, safer, and more effective healthcare to patients around the world. Hassan Ahmad is a co-founder of the Australian Medical Student Journal.
In the context of rural health, these obstacles stand paradoxically against the substantial potential a proper e-health system has to bridge the healthcare gap experienced in more remote areas. These rural and remote areas arguably have the most to gain from this commitment to a modern and efficient 21st century healthcare system that will help raise the standard of healthcare service and accessibility to that of urban areas. However, the government is currently facing the stark realities of delivering these solutions to the six
29
Contact: Professor Glenn Bowes , Associate Dean (External Relations), Faculty of Medicine, Dentistry and Health Sciences E-mail: gbowes@unimelb.edu.au Website: www.mdhs.unimelb.edu.au
SANT-RAYN PASRICHA
University of Melbournes Nossal Institute for Global Health PhD student, Sant-Rayn Pasricha, works with Melbournes leading clinical and research institutions to address iron deficiency in women and children throughout developing countries, such as India and Vietnam. Dr Pasricha is the recipient of one of six 2010 Victoria Fellowships from the Victorian Government, which is awarded to emerging leaders in engineering, science and technology. The fellowship will allow Sant-Rayn to work with the World Health Organisation in Geneva where he will be involved in shaping global anaemia policy. Through his experiences at the University of Melbourne, Sant-Rayn is able to translate his extensive research into developing global policies that have the potential to save millions of lives worldwide.
30
Mental Health Research Institute and the Universitys Melbourne Brain Institute; major expansion of the Walter and Eliza Hall Institute and the University of Melbournes Bio21 Institute; and the Peter Doherty Institute for Infection and Immunity, named in honour of the Nobel Laureate currently working within the faculty. The City of Melbourne is championing major transport and urban design projects within Parkville, which will add to Melbournes global reputation as a liveable city. These projects are creating new and exciting opportunities for the precincts amenities and connectivity. Commercialisation developments are also occurring, including Recaldent and the Bionic Eye project. Recaldent and emerging gingival vaccines have been developed by Professor Eric Reynolds group in the Melbourne Dental School. Recaldent is a milkbased bioactive food ingredient used to re-mineralise teeth and bones that is now added to chewing gum and toothpaste, generating significant health and commercial outcomes. Australia has been a world leader in medical bionics and now the University of Melbourne is part of the Bionic Vision Australia Consortium developing an advanced bionic eye that will
provide users with increased mobility and independence and potentially offer facial recognition and the ability to read large print. The co-location of both government research agencies (CSIRO) and major researchfocused corporations (CSL and IBM) are further extending such opportunities. Progress to date in this next phase of development of the historical Parkville health and medical research precinct has been extremely positive. The University of Melbourne is the number one university in Australia (36th in the world) and Australias top university in clinical, preclinical and health (18th in the world) and life sciences (32nd) according to The Times Higher Education World University Rankings 2010. In the field of clinical medicine and pharmacology, the Shanghai Jiao Tong ranks the University of Melbourne first in Australia (41st in the world). In the recent Excellence in Research for Australia assessment by the federal government, the University of Melbourne achieved the maximum rating of five (well above world standard) in 42 fields, including Biomedical and Clinical Science. There is increasing success across all Parkville precinct institutions in attracting competitive national
and international research funds. The recruitment of world-class research leaders and outstanding doctoral and postdoctoral students is ensuring that growth in physical capital is matched by a parallel growth in the numbers of research scholars and students to drive creativity and innovation. There is a sense of optimism towards health precincts and they currently enjoy policy support from governments. However, the future of precincts in Melbourne and many other countries is not set in stone, although early signs show that they deliver amazing outcomes. As we learn more about what are the critical success factors of such precincts we will need to move rapidly to promote those elements and to be vigilant as to the barriers to progress that may emerge. Governance structures are likely to be crucially important to ensure that the creativity and leadership is not stifled by bureaucratic structures and that institutional silos do not emerge. Universities, by the very nature of their mission, are well placed to exercise the influence and leadership that facilitates connectivity and provide the glue for the precinct. Professor James A. Angus, AO, FAA, Dean and Professor Glenn Bowes, Associate Dean,Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne
31
Contact: Heather Cavanagh, Associate Dean Faculty of Science, CHARLES STURT UNIVERSITY Tel: +61 2 6933 2726 E-mail: hcavanagh@csu.edu.au Website: www.industry.nsw.gov.au
Healthcare education
CSU is a leader of work-integrated learning, with a comprehensive suite of courses in areas such as pharmacy, nursing, medical imaging, forensic biotechnology, podiatry, medical science and physiotherapy. CSUs health and medical science course structures ensure theory is interspersed with clinical rotations, cooperative education and industry attachments. According to Head of CSUs School of Community Health, Associate Professor Julia Coyle, working in small professional groups is an emergent practice in Australia and internationally. As healthcare services become more integrated, CSU continues to embrace interdisciplinary collaboration as a standard way to work and teach, she says. With close industry ties and regular reviews by accrediting bodies, CSUs courses ensure its graduates are always in demand. Through patient care, research, and community service, students and staff play a major role in helping improve the health of people in
32
Healthcare education
Clinical Pharmacology, has set up an important collaboration with colleagues at Liaocheng Peoples Hospital in Shandong Province and Guangzhou Red Cross Hospital in Guangdong Province to develop innovative keyhole surgery techniques in children and newborns suffering from congenital heart defects. His work has led to significant reductions in child mortality and surgery recovery times. Currently CSUs School of Biomedical Sciences is involved in offshore teaching programs in, Hong Kong (Master of Pathology) and Ireland (Postgraduate Certificate in Emergency Medical Services Leadership and Management). The School has also launched its Bachelor of Science (Forensic Biotechnology) program at CSU in Ontario, Canada this year. These new international initiatives show the commitment of the School of Biomedical Sciences to the internationalisation of its courses and are supported by Charles Sturt Universitys reputation and experience as a world leader in distance education. The School of Biomedical Sciences invites everyone who is interested in study or research collaboration to visit its website. www.csu.edu.au/faculty/science/ biomed
the late 1990s/2000. Graduates from all courses are highly regarded by industry, and regularly gain employment before graduation. Many have gone on to be leaders in their chosen profession. Research and higher degree studies are a focus in the school. The research focus of the medical radiations and physic staff are broad and include; CR/DR, CT, MRI, ultrasound, molecular imaging, SPECT/CT, PET/CT, herbal medicine, and radiation therapy; medical and radiation physics. Successful research collaborations have been made both locally and internationally with various universities and clinical institutions. These collaborations have allowed the research to have impact both in clinical and the more fundamental sciences. Higher degree studies are all offered by distance education. CSU has a strong history in delivering quality courses, both undergraduate and postgraduate, by distance education. While CSU is a regional/ rural university with a strong focus in such areas, the medical radiation science degrees are also designed for students to meet all levels of professional challenges and for student to lead their profession into the future. The postgraduate courses offered in Medical Radiation Sciences include: Master of Medical Radiation Science general and with specialisations in Computed Tomography, Magnetic Resonance Imaging, Radiographic Interpretation and Nuclear Medicine; Master of Medical Ultrasound; Doctor of Health Science (a professional Doctorate) and Doctor of Philosophy.
The School of Dentistry and Health Sciences invites everyone who is interested in study or research collaboration to visit its website. www.csu.edu.au/faculty/science/ dentistry-health
33
The School of Nursing, Midwifery and Indigenous Health offers full-time and part-time research degrees at Master and Doctoral levels, which are supervised by highly regarded and well published nursing scholars experienced in both qualitative and quantitative methodologies. The School of Nursing, Midwifery and Indigenous Health invites everyone who is interested in study or research collaboration to visit its website. www.csu.edu.au/faculty/science/ nurse
The flexible delivery of distance education means that students can study in their home country at a time that suits them. CSU provides an excellent range of support tools for distance education students. CSU Interact is the virtual learning and teaching space where students and lecturers meet to build community, share knowledge and work together in an online scholarly environment. Its comprehensive communication system enables online forums, wikis, blogs, podcasts, access to library resources and assignment submission. Course material is designed with the distance education student in mind and aims to engage and promote active thinking and participation.
between the University and partners in industry, government and the community. Charles Sturt University is dedicated to maximising its research potential and is undertaking research in the health sciences in areas including; nuclear medicine, radiotherapy qualitative methods, rural nursing, workplace education, clinical decision making, chronic disease management, palliative and aged care, drug and alcohol, acute care, child and rural health. CSU has supervision capacity and experience in; nuclear cardiology, cardiovascular health, palliative care, cancer detection, cancer therapy, cancer survivorship, traditional Chinese medicine and western herbal medicine. For more examples, visit www.csu.edu.au/faculty/science/ faculty-research/projects
Healthcare education
SUCCESS STORIES
Matthew Haase, student from 2003-2005 Matthew Haase graduated from CSU with Distinction from the Bachelor of Medical Radiation Science (Nuclear Medicine). After several years experience, Matthew now heads a nuclear medicine facility which has had the recent addition of a state-of-the-art SPECT/CT system that includes capability for high quality SPECT, high quality diagnostic CT and fusion imaging between SPECT and CT. Senior Lecturer with the School of Dentistry and Health Sciences, Dr Janelle Wheat said, Matthew has had an exemplary career to date and now is back in regional Australia working in a management role in his chosen field. Dr Jason Steel, PhD student from 1999-2003 Dr Jason Steel graduated with a PhD from Charles Sturt University in 2004 after he finished his research work on development of a novel adenoviral-based gene vector for cancer gene therapy at the School of Biomedical Sciences. Dr Steel then went on to Maryland in the United States to work as a postdoctoral fellow at the National Institutes of Health, one of the foremost health research laboratories in the world. While working at NIH, Dr Steel won numerous research and travel prizes, and published his work on gene therapy for cancer in worldclass journals. Jennifer Azurin, Student in the Master of Health Services Management Talk about a drop in the water causing ripples in the ocean! says Jennifer. I am so grateful to the CSU academic staff for being the inspiration for a proposal I recently submitted to promote quality and a positive culture of continuous improvement across our healthcare organisation of over 5000 staff. I like to think this is a significant achievement for our small work unit, for the numbers it hopes to attract.
34
Contact: Anne Trimmer, Chief Executive Officer Medical Technology Association of Australia Tel: +61 2 9900 0650 E-mail: reception@mtaa.org.au Website: www.mtaa.org.au
ABOUT MTAA
The Medical Technology Association of Australia (MTAA) is the national association representing companies in the medical technology industry. MTAA aims to ensure the benefits of modern, innovative and reliable medical technology are delivered effectively to provide better health outcomes to the Australian community. MTAA represents manufacturers and suppliers of medical technology used in the diagnosis, prevention, treatment and management of disease and disability. MTAA members distribute the vast majority of non-pharmaceutical products used in the diagnosis and treatment of disease and disability in Australia. Our member companies also play a vital role in providing healthcare professionals with essential education and training to ensure safe and effective use of medical technology. MTAA represents the medical technology industry by contributing to policy development on state and federal government level and by consulting with key organisations and decision-makers. We deliver training and education programs
Medical Technology
There has been a shift in chronic disease management from acute care in hospitals to home or residential care. By 2050 Australia will see the number of people aged 65-84 years double and the number of people aged over 85 quadruple. Current spending on aged care is expected to more than double by 2049-50.
INDUSTRY OVERVIEW
The Australian medical technology industry includes a diversity of manufacturers and suppliers of medical technology, from emerging Australian companies to subsidiaries of global companies. The product range is equally diverse and includes disease screening technologies, therapies, equipment and supplies - everything from expensive, complex capital equipment (such as x-ray machines and MRI scanners) to simple items (such as bandages and syringes) and highly evolved technologies (such as implantable devices). The industry is also characterised by a high level of innovation, resulting in short life cycles for many products. Many medical devices The Australian market for medical technology is approximately two per cent of the global market. Because of its small size, this means that companies developing innovative technologies will always need to consider the potential return on investment in making a decision as to whether to bring a technology into Australia or invest in development of a new technology in Australia. Sales of medical technology in Australia in 2008-2009 were $7.4
36
Medical Technology
tailored to the specific needs of the industry and provide networking opportunities and platforms to share information with experts and peers. Ethical standards and compliance with applicable laws are critical to the medical technology industrys ability to continue its successful collaboration with healthcare professionals. MTAA has developed a Code of Practice facilitating ethical interactions between industry representatives and healthcare professionals.
and deliver radio waves to kill tumours; point-of-care diagnostics that result from the fusion of genomics and information technology; release of a pre-determined quantity of a drug stored in a silicon chip in a patients body on receipt of a remote wireless signal sent via an electrical current; and
In the next 10 years medical innovations will continue to transform the healthcare landscape. The miniaturisation of medical technologies will continue allowing even more minimally invasive and non-invasive procedures which will move care from hospitals to outpatient setting. Replacement organs and tissue engineering advances will provide new options for addressing serious conditions. Molecular and gene-based diagnostics will detect diseases such as cancer earlier in their progression, improving patient outcomes and lowering treatment costs. Medical technology of the future will include diverse and complex products such as: micro-sized nano-robots with tiny motors that roam the body
an extension of this chip technology to enable monitoring of patients at home for signs of heart attack and hypoglycaemia in order to release the appropriate drugs.
Health information technology innovations will allow critical medical data to be processed and transmitted rapidly, speeding up delivery of treatment and allowing information (such as internal defibrillators) to be monitored remotely by the surgeon via wireless connections. The vast potential that medical technologies represent will continue to transform patients lives well into the future.
37
Industry & Investment NSW Tel: +61 2 9338 6624 Fax: +61 2 9338 6890 E-mail: dkldsgjskdgaj.com.au Website: www.industry.nsw.gov.au
38
The sensor sends data to a small matchbox-size transmitter (SIMpod) connected to a wireless network throughout the facility. The network communicates with a web-enabled central system housed within the aged care facility. The monitoring system has a sophisticated software program that uses a series of patented algorithms to analyse data from the sensor worn by each resident, so that it builds a profile of each individuals continence patterns over a 72-hour period so that a pattern can then be predicted allowing staff to develop a personalised care plan. SIM was launched in the Australian market in October 2009 and has rapidly gained support from the residential aged care sector, the community and health professionals.
Dubbed The Authenticator, the product will soon be used by a European company to authenticate the entire production volume of one of its most successful drug products, challenging the multibillion dollar international trade in counterfeit medicines. This product helps manufacturers take control of their distribution channels, enforce supply contracts, minimise illegal warranty claims, and support customs and law enforcement efforts to stop pharmaceutical counterfeiting. www.datatracedna.com
AIMEDICS has developed the HypoMon, a breakthrough noninvasive sleep monitor and alarm for hypoglycaemia in people with Type 1 (insulin dependent) diabetes. The Hypomon uses a belt containing a smart electronic sensor and transmitter worn comfortably around a persons chest as they sleep. The belt non-invasively monitors physiological changes inside the wearers body through a range of complex measurements including electrocardiograph (ECG), movement and pre-sleep blood glucose level. If the device detects hypoglycaemia occurring, the system sets off a separate alarm to wake the person or a carer allowing the condition to be promptly and safely treated. Consistent treatment of such events will support better short and long term health outcomes. The product is expected to be on the market this year. www.hypomon.com
In 2010 Simavita agreed to work with Denmarks Abena Group in a non-exclusive marketing and distribution agreement to rollout SIM across Europe. Apart from improving the quality of life for aged care residents and their carers, SIM can save up to 50 per cent of the cost of labour associated with manual continence assessments. www.simavita.com
39
CRICOS: 00116K
40
www.mdhs.unimelb.edu.au
Cancer imaging
Contact: Peter Macs Communications Tel: +61 3 9656 5883 E-mail: emma.liepa@petermac.org Website: www.petermac.org
Scans of a patient on the crizotinib study. The scan shows a dramatic and early response in the extensive non small cell lung cancer tumour and distant metastatic disease.
Highlights of this research have included involvement in real-time assessment of new cancer therapies in phase I trials. Peter Mac is leading the analysis of PET imaging results for a worldwide trial using a molecular targeted agent for melanoma. The outcomes of this trial have attracted global media interest with Peter Mac images featuring in the New York Times, The Economist and La Recherche. Because of Peter Macs expertise in the use of PET for drug validation, new treatments for giant cell tumours of bone, lung cancer and other malignancies have been made available to Australian patients.
41
DEVICE TECHNOLOGIES
Device Technologies Pty Ltd has become a national leader in supply of specialty medical and surgical devices to all Australian public and private healthcare pro iders
Since 1992, Device Technologies has been supplying medical equipment and consumables to hospitals and healthcare professionals throughout Australia and New Zealand. Today, the company employs in excess of 200 people and operates sales offices in every Australian state, and in Auckland, New Zealand, and is the largest independent medical company in Australasia. The company provides medical and surgical staff of the public Device Technologies represents a vast diversity of independent global manufacturers that develop and launch innovative medical technologies. In addition to the launch of innovative technology, Device Technologies coordinates a number of clinical trials required to substantiate product claims and efficacy. Any introduction of new technology requires research, training, and procedural support
42
DEVICE TECHNOLOGIES
both pre and post the sale. Device Technologies partnership with physicians, surgeons and clinical teams facilitates best practice through the education and support programmes that coincide with any product launch. These tangible benefits provide added value at no additional cost to the customer. Device Technologies adheres to a quality management system compliant with AS/NZS ISO 9001. The accreditation covers the administration, installation and servicing of such devices. It contains 900 ARTG (Australian register of therapeutic goods) inclusions for medical devices across 18 areas of specialty. These include anaesthesia and critical care, cardiac specialties, ophthalmology, optometry, orthopaedics and gynaecology. They are also involved in surgery such as plastic and reconstructive surgery, radio surgery and robotic surgery. They have a strategic partnership with Health Robotics, a global leading supplier of life-critical intravenous medication preparation, compounding, and dispensing robots. On an interventional level, Device Technologies sources materials for endoscopy, laparoscopy, and urology and vascular access. Its products can be divided into three main categories:
SynCardia temporary Total Artificial Heart as a bridge to donor heart transplant for people dying from end-stage biventricular failure. The 50-year-old patient, who only had weeks to live prior to receiving the Total Artificial Heart, has since recovered his kidney and liver function. The following month, the SynCardia temporary Total Artificial Heart was awarded the 2010 Kerrin Rennie Award for Excellence in Medical Technology by the Medical Technology Association of Australia (MTAA). The Total Artificial Heart is the only device that provides immediate, safe blood flow of up to 9.5 L/min through both ventricles. Device Technologies is a national leader in the growth of the medical technology industry. Equipped with the expertise, skill and capabilities, the company has positioned itself to market and sell a range of high quality capital equipment and technologically innovative medical device consumables. As such, they offer innovative solutions to todays medical problems and help improve the overall quality of life for patients.
43
Contact: CL Plastics and Consultants Pty Ltd Tel: +61 3 9782 3033 Website: http://clplastics.com.au/
to the technical problems are utilised. Furthermore, CL Plastics and Consultants Pty Ltd is an ISO 9001:2008 certified company, meaning that they are committed to international standards for the manufacturing industry. CL Plastics has become heavily involved in the field of biomedical engineering through an internal holding company called Biomedical. CL Plastics is involved in the production of a variety of medical products. These include high-volume disposables, such as syringes and blood bags, as well as continuous positive airway pressure (CPAP) devices, nebulisers, blood glucose monitoring devices, artificial organs, biomechanical joints, heart valves, drug delivery
devices, digital signal processing hearing aids, contact lenses, in-vitro diagnostic devices and more. The growth of plastics use in medical applications has transformed the healthcare industry to become much more effective, sustainable and efficient. Plastics have a number of advantages over other materials used in medical applications such as metal, glass and ceramics. Plastics are a lot cheaper to produce than other materials, and have considerable advantages in terms of their sterilisation capabilities. Sterilisation capacity has quickly become the key characteristic of materials when deciding their use in various medical applications such as surgery. The injection moulding production of plastic products is much quicker, resulting in the fast
44
turnover rates that are particularly desirable for the production of high volumes of medical disposables. Furthermore, plastics have significant advantages in that they have exceptional design flexibility, biocompatibility and capacity to form complex shapes depending on the production method. This along with the ability of plastic products to be tailor-made to meet certain requirements, has increased development in high-tech applications such as implantable pacemakers, artificial organs and biomechanical joints.
medical devices requires extensive experience and cross-functional expertise in fields of plastic production such as injection moulding, rotational moulding, thermoforming and extrusion. Furthermore, CL Plastics uses its expertise in the wide variety of other materials is also used for the manufacture of medical devices. These qualities are rarely found in a plastics production company as they are in CL Plastics. The private proprietors of CL Plastics and their consultants have a long and diversified experience in the plastics
solving capabilities of plastics engineers at the company to tackle medical problems and improve the overall quality of life of patients. Such collaboration can lead to innovative solutions to medical problems. CL Plastics also operates an ISO 8 clean room. This is a sterile room used to manufacture products with exceptionally reduced contamination of environmental pollutants. This has allowed CL Plastics to produce medical applications with maximal purity that can be used in sterile postoperations, such as in surgery. This is an important capability for a company involved in medical application production, as safety and quality assurance in the healthcare industry is an area which cannot be compromised. Infections during hospital stays and surgery occur frequently and often have fatal consequences. Thanks to these capabilities and the growing attractiveness of plastic use in medical applications, CL Plastics has become a national leader in the production and innovation of plastic medical applications. In the future, the company will be in a prime position to lead the growth of this industry, and it has the expertise, skill and capabilities to offer innovative solutions to todays medical problems and consequently play a significant role in improving overall patient quality of life.
Costs and time pressures in healthcare have seen plastics take over from other materials in the production of medical disposables. The worldwide demand for plastics in the production of medical disposables is expected to reach US$70 billion by the end of 2012. CL Plastics and consultants PTY has contributed to this worldwide growth. The growth of the plastics market in developing nations such as China and India is expected to continue at an enormous rate and the geographical position of Australia puts CL Plastics in a prime position to lead the way in the growing involvement of plastics in the healthcare industries. It is important to note that the design and production of plastic
industry and the company prides itself on the knowledge bank in their company. Bio-medical, a separate holding company within CL Plastics, offers professionals within the healthcare industry a consultation service to seek the expertise and problem-
THERMOPLASTICS
CL Plastics offers an extensive range of medical-grade thermoplastics. Designed specifically for the medical, pharmaceutical and biotechnology sectors, these are designed to replace existing solutions made of stainless steel, titanium, glass or ceramics. Thermoplastics reduce weight and are commonly more resistant to sterilisation methods, offer anti-static performance and resistance to high energy radiation. The thermal resistant properties of CL Plastics plastic injection products also give them resistance to hot weather conditions and deflection temperature qualities, while also having a recyclable quality and UV stabilisation properties.
45
Pharmaceuticals
HOSPIRA AUSTRALIA
46
Pharmaceuticals
HOSPIRA AUSTRALIA
calculation, programmable delivery schedules, delivery from multiple sources, and backpriming function for air elimination. This technologydriven, automated approach aims to improve productivity and clinical outcomes, while enhancing patient safety. The GemStar Infusion Systems consist of general infusion and pain management versions providing up to seven therapies including patient controlled analgesia (PCA). GemStar relies on being modular and flexible, offering customisable configurations to tailor treatment protocols for a range of clinical scenarios. Hospira Australia also provides speciality medical equipment such as the Receptal Waste Disposal System, a closed portable suction system to isolate surgical waste. Hospira Australias invasive monitoring systems consist of the Q2 Plus CCO/SO2 monitor, and the SAFESET family of vascular and cardiac catheters, and disposable pressure transducers. These allow
created to mimic versions of an innovator biopharmaceutical product after this innovator product expires its patent. Developing a biosimilar employs a more involved process than duplicating a generic pharmaceutical, as biopharmaceuticals consists of proteins or nucleic acids which contain structures of vastly greater complexity compared with traditional small-molecule pharmaceuticals.
haematological field, including its first launched biosimilar: Retacrit (epoetin zeta), a treatment for anaemia associated with chronic renal failure or those receiving chemotherapy. The introduction of Retacrit has helped reduce the cost of medications in its drug class by approximately 20 per cent in Europe, while improving patient access to this therapy. In 2009, Hospira built support for legislation in the United States to help create future pathways in biosimilar approval, thereby promoting further biomedical innovation. Most recently, Hospira Australia has launched Hospiras second biosimilar, Nivestim (filgrastim), indicated in the prevention of neutropaenia associated with cancer or those receiving cancer chemotherapy. Nivestim has also been authorised for the European market and it is the first biosimilar to receive Australian approval. Recent agreements with leading biopharmaceutical manufacturers have been made with the intention of making Hospira one of the industrys largest developers of biosimilars. With this promising new field of treatment technology, Hospira continues to innovate towards its philosophy of expanding global access to affordable lifesaving medicines.
Hospira has one of the industrys broadest portfolios, with approximately 200 generic injectable products used in acute-phase care, intensive care and anaesthetics
clinicians a direct method of assessing a patients haemodynamic profile the ability for the cardiovascular system to supply the body tissues by tracking real-time changes in blood pressure. The development of biosimilars consequently occurs through biotechnological manipulation to artificial proteins and the result is similar, but not identical, to the innovator product. For this reason, new biosimilars must submit to a rigorous testing and approval process. In the last two years, Hospira has been developing a number of biosimilars for use in the
A FUTURE IN BIOPHARMACEUTICALS
Biosimilars, also known as follow-on biologics, are biopharmaceutical medicines
47
Head office (Melbourne) Tel: +61 3 9804 8887 Fax: +61 3 9804 8889 Email: tony.lenevez@hwims.com.au Website: www.hwims.com.au Sydney Tel: +61 2 9499 3011 Fax: +61 2 9499 3010 Email: lachlan.mcphail@hwims.com.au
Looking to Australia?
Hamilton Watts provides professional visa and migration services to both individuals and businesses.
With over 20 years experience in the visa and migration industry, Hamilton Watts Migration Services is one of Australias leading immigration consultancies. At the core of our business are several former senior managers and officers of the Australian Department of Immigration, providing a level of experience and know-how unequalled by any other agency. Hamilton Watts has offices located in both Melbourne and Sydney and we represent clients throughout Australia and overseas. Every Hamilton Watts Consultant is a registered Migration Agent with the Migration Agents Registration Authority (MARA) and is a member of the Migration Institute of Australia (MIA). We are committed to providing our clients the highest quality of service by adhering to strong ethical standards.
for your workforce and new staff members. We can also provide visa and permanent residence migration services for senior managers who will lead the new enterprise. It is critical that businesses which sponsor workers are aware of their sponsorship obligations. Breaches of these can result in substantial fines and sponsorship cancellations. Hamilton Watts provides free training to our client companies human resources and administrative staff on these obligations and associated record keeping. We also use custom-built IT systems that allow us to assist our client companies in tracking their employees visa details to ensure that they always comply with their visa conditions and visa validity periods.
their primary medical qualification in a country other than Australia. Doctors can apply for either a temporary or permanent visa. Doctors seeking permanent residency in Australia must hold full medical registration. Opportunities are also excellent for nurses, with permanent and temporary work available across all fields of nursing. You can be in or outside Australia when you apply for a visa to work as a nurse. Australia offers the General Skilled Migration Program for those who are not sponsored by an employer and who have skills in particular occupations required in Australia. Applicants must be aged 18 to 45, have good English skills and recent skilled work experience. The most recent Skilled Occupations List shows 66 occupation types relating to the healthcare and medical fields, including medical and nursing administrators, general practitioners, nuclear medicine technologists, pathologists, dentists, audiologists and a wide range of specialist doctors.
Skilled migration
48
CRICOS: 00116K
www.mdhs.unimelb.edu.au